The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correction to Esteller et al., N Engl J Med 343(19):1350-1354 November 9, 2000.

Correspondence
PreviousPrevious
Volume 344:686-688 March 1, 2001 Number 9
NextNext

The DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
 by Esteller, M.
-PubMed Citation
To the Editor: Esteller and colleagues (Nov. 9 issue)1 claim that methylation of the O6-methylguanine-DNA methyltransferase (MGMT ) promoter is associated with improved responsiveness to carmustine and prolonged survival in patients with high-grade gliomas. We believe there are methodologic flaws in the authors' study that call these results into question. First, the patients in the study were treated with a combination of surgery, radiation therapy, and chemotherapy with cisplatin and carmustine. We do not believe the response to carmustine is a discernible end point in this trial, because multiple treatments were administered along with carmustine.

Second, although the . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.